Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

Scientists from the University of Sharjah have found that a naturally growing aromatic plant contains ingredients with the ...

Aspirin has been shown to effectively reduce recurrence rates and improve disease-free survival,” said Anna Martling, MD, PhD.

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer ...

Rather than activating multiple effectors, mutant KRAS signals preferentially through the RAF–MEK–ERK pathway ... do not sufficiently displace PI3K from active KRAS. In addition, active ...